More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Shire's $30 billion proposal to acquire Baxalta, the newly spun-off company from Baxter Healthcare, would give Shire a $6 billion biopharmaceutical company with a rare-disease focus. What would a combined Shire and Baxalta be? Baxalta, which only...
DCAT Value Chain Insights

What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or newly approved drugs. This year has seen the market entry of several drugs pegged as future blockbusters. So what new...
DCAT Value Chain Insights

Approvals and advisory committee recommendations last week by the US Food and Drug Administration and the European Medicines Agency have put the markets for hepatitis C and anti-cholesterol drugs into greater play with several blockbluster...
DCAT Value Chain Insights

Teva Pharmaceutical Industries has dropped its pursuit of Mylan N.V. and instead has made a $40.5 billion offer to acquire the global generics business of Allergan (the new corporate name of the combined Actavis and Allergan) in a friendly...
DCAT Value Chain Insights

Celgene's $7.2 billion bid to acquire the biopharmaceutical company Receptos is the latest move by the company as it seeks to more than double its sales to $21 billion by 2020. So what is behind the growth strategy of Celgene? DCAT Value Chain...